



## KIRA PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH CHIEF BUSINESS OFFICER, CHIEF MEDICAL OFFICER AND CHIEF COMMERCIAL OFFICER, CHINA

**CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (February 23, 2021)** CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (February 23, 2021) – Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the addition of three seasoned pharmaceutical leaders, Kathy He, Richard Lee, MD, and Dana Zhang, MD, to its expanding team. Ms. He joins Kira as Chief Business Officer; Dr. Lee joins as Chief Medical Officer; and Dr. Zhang as Chief Commercial Officer, China, strengthening the executive team at a key time of growth for the company.

“We are thrilled to welcome such a high caliber of individuals to our executive team. This is an exciting time for the company – with our first program now in the clinic and two additional complement-targeted therapies moving to clinical trials over the next 18 months,” said Frederick Beddingfield, MD, PhD, Chief Executive Officer of Kira Pharmaceuticals. “Kathy’s keen business acumen, wide-ranging business leadership, and global capital market experiences are invaluable to Kira in developing corporate strategy, optimizing the financing of the company, and establishing strategic partnerships. Richard brings extensive experience in the development of complement therapies, adding clinical and medical affairs expertise to the leadership team as we drive our lead clinical-stage asset, P014, and the rest of the pipeline forward. Dana brings her passion and extensive breadth and depth of leadership in developing and commercializing complement therapies in Asia and adds significant expertise to our growing team.”

Ms. He joins Kira after serving as CBO and Head of Corporate Development at Abbisko Therapeutics, where she led the company's B and C financing rounds, raising over \$100M from internationally renowned venture investors as well as sourcing and executing cross-border and domestic strategic partnerships. Prior to Abbisko, Ms. He served as a partner at several investment firms, was founder and CEO of Vivregen, and led commercial launches of several blockbuster drugs in the US at multi-national companies including Takeda Pharmaceuticals, Merck and Abbott.

"It's a privilege to be joining Kira at such an exciting time for the company and the field of complement medicine," said Ms. He. "Targeting the innate immune system is increasingly recognized as crucial for treating immune-mediated diseases. I'm looking forward to working with the leadership team to expand Kira's pipeline of complement-targeting therapies and help chart a path to bring important new therapeutics to patients."

Dr. Lee comes to the Kira team after serving as Head of Hematology at Alexion Pharmaceuticals, a global company specializing in the development of complement therapies. Dr. Lee has also served in clinical and medical affairs leadership roles at several well-known pharmaceutical and biotechnology companies including Roche, Genentech, Millennium/Takeda, Bayer Pharmaceuticals and Bristol-Myers-Squibb, leading global teams developing products ranging from large biologics to small molecules. Dr. Lee has been instrumental in the development and launch of a number of first-in-class medicines throughout his career.

"I'm very excited to draw on my wide-ranging biopharma experience to advance Kira's clinical strategy and direction," said Lee. "Growing with an early-stage company at the cutting edge of immune-mediated disease therapies with an innovative pipeline like Kira's is a dream. I am inspired and proud to contribute to Kira's mission to serve patients by developing best-in-class therapies for those who need them most."

Dr. Zhang joins the Kira executive team with 20 years of biopharmaceutical experience, including 16 years of experience in the rare disease and orphan drug market. Most recently, Dr. Zhang served as General Manager of Greater China for Alexion Pharmaceuticals, where she led the successful approval of Soliris in China as well as approvals and commercialization in Taiwan and Hong Kong. In her role at Alexion, she guided all aspects of commercial operations strategy and P&L management in Taiwan, Hong Kong and China. Prior to her nine years at Alexion, Dr. Zhang was Head of Business Development for Celgene China, Country Manager for Actelion China, led the successful launch of Tracleer, and held consulting roles at Genzyme and Keller Pharma Consulting.

“I’m incredibly excited to be joining the Kira team at such a pivotal moment for the company,” said Dr. Zhang. “I look forward to utilizing my diverse medical and business knowledge to bring Kira’s ground-breaking complement-targeting therapies to patients in dire need of therapies wherever they live, including in China and many other Asian countries where complement-specific therapies are simply unavailable.”

## **About Kira Pharmaceuticals**

Kira Pharmaceuticals is a biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. Enabled by its LOGIC drug discovery platform, the company is committed to advancing first-in-class and best-in-class therapies to transform the lives of patients with complement-driven diseases. With offices in Cambridge, Massachusetts and an R&D center in Suzhou, China, Kira Pharmaceuticals is committed to establishing a global footprint and advancing life-changing therapies to patients around the world.

For more information, please visit [www.kirapharma.com](http://www.kirapharma.com).

### **Media Contact**

Lisette Steele

Verge Scientific Communications

[lsteel@vergescientific.com](mailto:lsteel@vergescientific.com)

202.930.4762

## 科越医药扩大执行领导团队加入首席业务官，首席医疗官和首席中国区商务官

美国马萨诸塞州剑桥市和中国江苏省苏州市（2021年2月23日）-科越医药，一家致力于研发新一代补体靶向药物来治疗免疫介导疾病的全球生物技术公司，今天宣布三位经验丰富的制药领导者何奇志女士（Kathy He）担任首席业务官，Dr. Richard Lee担任首席医学官，张丹煜女士（Dr. Dana Zhang）担任中国首席商务官，在公司成长的关键时刻加入其不断扩大的执行领导团队。

“我们很荣幸并欢迎如此优秀的人才加入我们的执行团队。对于公司来说，这是一段激动人心的时刻-我们的首创生物药现已在临床中，另外两种针对补体的疗法也会在未来18个月内进入临床试验，”科越首席执行官贝丁菲尔德博士（Frederick Beddingfield, MD, PhD）表示。“Kathy敏锐的商业头脑，广泛的商业领导力和全球资本市场经验对于科越在制定公司战略，优化公司融资以及建立战略合作伙伴关系方面具有不可估量的价值。Richard在补体疗法的开发方面拥有丰富的经验，为领导团队增加了临床和医疗方面的专业知识，为我们领先的临床阶段生物药P014以及其余产品推动开发的方向。Dana在亚洲补体治疗的开发和商业化方面拥有的热情和卓越的领导才能，为我们不断壮大的团队提供了丰富的专业知识。

Kathy女士在加入科越前在和誉生物（Abbisko Therapeutics）担任首席业务官和公司发展部负责人，制定跨境与境内合作战略并成功获得多个项目的全球或大中华区权益的授权，同时领导公司B轮和C轮的融资，成功从国际知名的风险投资者筹集了超过1亿美元。在加入和誉之前，她曾在多家投资公司担任合伙人，是Vivregan的创始人兼首席执行官，并在包括武田（Takeda Pharmaceuticals），默沙东（Merck）和雅培（Abbott）等跨国公司中领导了多款重磅畅销药物在美国的商业发展。

Kathy女士说：“在如此激动人心的时刻加入科越和补体医学领域是我的荣幸”“对天然免疫系统靶向治疗的认知正日益增长，这也是治疗免疫介导性疾病关键所在。我期待与领导团队合作，扩大科越的补体靶向疗法产品线，并帮助规划为患者带来创新疗法的途径。”



Dr. Richard Lee 加入科越团队之前在瑞颂制药 ( Alexion Pharmaceuticals , 一家专门从事补体疗法开发的全球公司 ) 担任血液学领域负责人。他还曾在罗氏 ( Roche ) , 基因泰克 ( Genentech ) , 武田 ( Millennium / Takeda ) , 拜耳制药 ( Bayer Pharmaceuticals ) 和百时美施贵宝 ( Bristol-Myers-Squibb ) 等几家著名的制药和生物科技公司担任临床和医疗事务领导职务, 带领了全球团队开发从大型生物制剂到小分子, 在其职业生涯中一直致力于开发和推出多个创新药物。

Dr. Lee 表示: 我很高兴能够利用自己在生物制药领域的丰富经验来推进科越的临床策略和方向; 与科越这样的创新团队在免疫介导的疾病疗法领域中一起成长, 并为科越的发展做出贡献, 我为此而感到自豪。因为科越为患者带来了创新的疗法。 ”

张丹煜女士加入科越执行团队之前拥有 20 年的生物制药经验, 其中包括 16 年的罕见病和孤儿药物市场经验。之前曾担任瑞颂制药 ( Alexion Pharmaceuticals ) 大中华区总经理 9 年, 负责大中华区的商业运营策略和损益管理, 领导了舒立瑞 ( Soliris ) 在中国的成功获批, 以及在中国台湾和香港地区的成功上市和相关适应症的医保覆盖。在 Alexion 任职之前, Dana 曾担任新基制药 ( Celgene ) 中国业务发展部主管, 爱可泰隆 ( Actelion ) 中国区经理, 成功领导了波生坦 ( Tracleer ) 的上市, 并曾在健赞 ( Genzyme ) 和 Keller Pharma Consulting 担任咨询职务。

张丹煜女士表示: “在如此关键的时刻加入科越团队, 我感到非常兴奋, 我期待利用我丰富的医学和商业知识, 将科越突破性的补体靶向疗法带给急需治疗的患者, 无论他们身在何处, 包括在中国和其他许多没有补体疗法的亚洲国家。 ”

## 关于科越医药

科越医药是一家致力于开发针对补体介导疾病的免疫疗法的生物技术公司。公司凭借自己的 LOGIC 药物发现平台, 致力于推进首创疗法及同类最佳疗法, 以此彻底改善补体介导性疾病患者的生活。科越医药在美国马萨诸塞州剑桥市设有办事处, 并且在中国苏州和上海设有研发中心, 以此致力于建立全球足迹, 在全球推广能够改善患者生活的疗法。

更多详情, 请访问网址 [www.kirapharma.com](http://www.kirapharma.com)。



**媒体咨询**

马益

yi.ma@kirapharma.com

(86)138-6200-1240